| Approved on: | 2026-05-05 |
| Brief purpose of the study: | This study aims to better understand the range of symptoms and immune findings in people with alpha-gal syndrome (AGS), identify distinct clinical subgroups, and develop tools for measuring disease severity for use in future clinical trials. |
| Brief summary of what participants will be asked to do: | Eligible participants will complete an online questionnaire about their symptoms and health history and provide a blood sample at the MU Clinical Trials Support Unit (CTSU). |
| Basic eligibility criteria: | Any individual who has been diagnosed with alpha-gal syndrome is eligible to participate. |
| Study contact for more information: | alphagal@health.missouri.edu |
| IRB Number: | 2133646 MU |
